Atopic Dermatitis

By setting higher treatment goals, the AHEAD recommendations emphasize the importance of achieving optimal targets for both skin clearance and itch relief in atopic dermatitis.

Results from the study highlight that the therapy improves AD symptoms over time, with 71.9% of participants achieving substantial improvement.

The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.

The study found that after 4 weeks of using the action plan, AD severity decreased markedly, with many patients achieving mild AD status.

The study found 95.8% of ocular AEs occurred in AD patients, while SA patients reported only 4.2% of these events.

Patients with AD and psoriasis both report diminished levels of happiness compared to the general population.

Researchers stated the integration of wearable sensors with AI could potentially revolutionize care for patients with atopic dermatitis.

Learn more about the OX40-OX40L pathway and 2 drugs heading toward phase 3 trials.

Researchers suggested that itch control is key in reducing disease burden and improving life quality for patients with psoriasis and atopic dermatitis.

John Browning, MD, FAAD, FAAP, MBA, discusses the new online platform that allows young patients to share their skin journey with others.

Kindred spoke with Dermatology Times to discuss AbbVie's recent Science of Skin event and improving access to equitable dermatological care.

Jared Gollob, MD, shares highlights of Kymera Therapeutics' recent JID publication.

Kristine Kucera, MPAS, PA-C, DHS, discusses her patient's challenging atopic dermatitis that was eventually cleared with upadacitinib.

Researchers said they hope this consensus guides prescribing decisions among clinicians and encourages development of a standard approach.

The 15-piece questionnaire is designed to be quick and easy to use during consultations, with particular benefits across numerous specialties.

A growing body of research is dedicated to understanding how various climatic elements impact AD.

The study focused on the use of Internet resources, number of medical consultations, and factors influencing treatment outcomes.

This article represents the first time the news has been shared with the public. Turn's Founder and CEO, Bradley Burnam, shares details.

Data from a retrospective analysis demonstrated that patients with moderate to severe alopecia areata are at a higher risk of developing atopic dermatitis compared to those with mild alopecia areata.

Learn more about the in-depth topics covered in the July 2024 supplement of Dermatology Times.

Generation Z patients had lower atopic dermatitis severity but similar disease perception compared to Millennial patients.

Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.

A recent study saw a “significant” decrease in allergen-specific IgE levels over a 1-year period of dupilumab therapy in children with atopic dermatitis.

Robert Posnick, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving hyperpigmentation and alopecia areata.

Linda Stein Gold, MD, reviews data presented at SPD and elaborates on study design, methodology, and results.

Mona Shahriari, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis in patients with skin of color.

Jenny Murase, MD, and Elizabeth Kiracofe, MD, highlighted key clinical considerations to optimize atopic dermatitis care for patients during pregnancy, prepregnancy, postpartum, and breastfeeding.

Tapinarof cream 1% has proven to be an effective and safe treatment for atopic dermatitis in diverse populations, according to a poster presented at the SPD's annual meeting.

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.